Literature DB >> 25088385

Influence of central nervous system-acting drugs on results of cognitive testing in geriatric inpatients.

M Gogol1, H Hartmann, S Wustmann, A Simm.   

Abstract

INTRODUCTION: Growing evidence shows a high correlation between extensive use of central nervous system-acting drugs (CNSADs) in elderly patients and adverse drug reactions (ADRs) such as falls, fractures, and mortality. RESEARCH QUESTION: Are results of cognitive testing with the Mini Mental Status Examination (MMSE) influenced by use of CNSADs?
SETTING: Geriatric inpatient service for acute, subacute, and rehabilitation care.
METHODS: Secondary combined analysis of two prospective, single-center study cohorts (PROPSYC, 2011 and AGE OUT, 2012) with identical procedure for the MMSE at a tertiary hospital.
RESULTS: Overall, 395 patients were included, 144 male (M) and 251 female (F). Mean age was 80.0 ± 8.4 years (M 76.7 ± 9.1, F 81.9 ± 7.3, p = 0.0000). Mean MMSE points were 22.9 ± 4.8 (M 23.2 ± 4.6, F 22.6 ± 5.0, p = 0.211). In total, 258 patients (65.3 %) used drugs with potential adverse cognitive properties. Analgesics with central activity were given to 117 of 395 patients (29.6 %). Low-potency opioids (tramadol hydrochloride, tilidine) were identified in 60 patients and high-potency opioids in 57 patients. Antidepressants were used in 66 patients, benzodiazepines in 26, and hypnotics in 11, while 38 patients received other CNSADs. We only found significant correlations with the results of cognitive testing for sedatives (diazepam and oxazepam, Pearson's r - 0.79, p = 0.05), but not for lorazepam.
CONCLUSION: Our analysis shows an influence of sedatives (diazepam and oxazepam, but not lorazepam) on cognitive testing with the MMSE in users of CNSADs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25088385     DOI: 10.1007/s00391-014-0654-5

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  87 in total

1.  Persistent pain in nursing home residents.

Authors:  J M Teno; S Weitzen; T Wetle; V Mor
Journal:  JAMA       Date:  2001-04-25       Impact factor: 56.272

2.  Fractures in users of antidepressants and anxiolytics and sedatives: effects of age and dose.

Authors:  P Vestergaard; D Prieto-Alhambra; M K Javaid; C Cooper
Journal:  Osteoporos Int       Date:  2012-06-06       Impact factor: 4.507

Review 3.  Psychoactive drug abuse in older adults.

Authors:  Linda Simoni-Wastila; Huiwen Keri Yang
Journal:  Am J Geriatr Pharmacother       Date:  2006-12

4.  Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.

Authors:  Cheryl L P Vigen; Wendy J Mack; Richard S E Keefe; Mary Sano; David L Sultzer; T Scott Stroup; Karen S Dagerman; John K Hsiao; Barry D Lebowitz; Constantine G Lyketsos; Pierre N Tariot; Ling Zheng; Lon S Schneider
Journal:  Am J Psychiatry       Date:  2011-05-15       Impact factor: 18.112

5.  One hundred seventy two deaths involving the use of oxycodone in Palm Beach County.

Authors:  Barbara C Wolf; Wendy A Lavezzi; Linda M Sullivan; Lisa M Flannagan
Journal:  J Forensic Sci       Date:  2005-01       Impact factor: 1.832

6.  Psychotropic drug use in community-dwelling elderly people-characteristics of persistent and incident users.

Authors:  Maria Rikala; Maarit Jaana Korhonen; Raimo Sulkava; Sirpa Hartikainen
Journal:  Eur J Clin Pharmacol       Date:  2011-02-05       Impact factor: 2.953

Review 7.  Meta-analysis of the impact of 9 medication classes on falls in elderly persons.

Authors:  John C Woolcott; Kathryn J Richardson; Matthew O Wiens; Bhavini Patel; Judith Marin; Karim M Khan; Carlo A Marra
Journal:  Arch Intern Med       Date:  2009-11-23

8.  Polypharmacy and health beliefs in older outpatients.

Authors:  Michelle I Rossi; Amanda Young; Robert Maher; Keri L Rodriguez; Cathleen J Appelt; Subashan Perera; Emily R Hajjar; Joseph T Hanlon
Journal:  Am J Geriatr Pharmacother       Date:  2007-12

9.  Television viewing time and mortality: the Australian Diabetes, Obesity and Lifestyle Study (AusDiab).

Authors:  D W Dunstan; E L M Barr; G N Healy; J Salmon; J E Shaw; B Balkau; D J Magliano; A J Cameron; P Z Zimmet; N Owen
Journal:  Circulation       Date:  2010-01-11       Impact factor: 29.690

10.  Antidepressive therapy with escitalopram improves mood, cognitive symptoms, and identity memory for angry faces in elderly depressed patients.

Authors:  Egemen Savaskan; Sandra E Müller; Andreas Böhringer; André Schulz; Hartmut Schächinger
Journal:  Int J Neuropsychopharmacol       Date:  2007-08-13       Impact factor: 5.176

View more
  4 in total

1.  DEL-FINE: a new tool for assessing the delirogenic properties of drugs of relevance for European pharmacotherapy.

Authors:  Birgit Böhmdorfer; Sonja Rohleder; Martin Wawruch; T J M van der Cammen; Thomas Frühwald; Christian Jagsch; Susanne Melitta Maria Janowitz; Marietta Nagano; Mirko Petrovic; Ulrike Sommeregger; Bernhard Iglseder
Journal:  Z Gerontol Geriatr       Date:  2015-08-19       Impact factor: 1.281

2.  Protective Effect of Celecoxib on Early Postoperative Cognitive Dysfunction in Geriatric Patients.

Authors:  Yangzi Zhu; Rui Yao; Yan Li; Congyou Wu; Lei Heng; Meiyan Zhou; Li Yan; Yan Deng; Zhe Zhang; Lei Ping; Yuqing Wu; Shengtao Wang; Liwei Wang
Journal:  Front Neurol       Date:  2018-08-07       Impact factor: 4.003

3.  Lack of direct involvement of a diazepam long-term treatment in the occurrence of irreversible cognitive impairment: a pre-clinical approach.

Authors:  Louise Carton; Candice Niot; Maéva Kyheng; Maud Petrault; Charlotte Laloux; Camille Potey; Marie Lenski; Régis Bordet; Julie Deguil
Journal:  Transl Psychiatry       Date:  2021-12-03       Impact factor: 6.222

4.  FKBP51 is associated with early postoperative cognitive dysfunction in elderly patients undergoing hip fracture surgery.

Authors:  Li-Wei Wang; Mei-Jun Zhu; Yan Li; Sheng-Tao Wang; Mei-Yan Zhou; You-Jia Yu; Zheng-Liang Ma
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.